- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05009654
The Effect of Leucine on Carnitine Transport to Skeletal Muscle (ROL)
August 11, 2021 updated by: Robert Olek, Gdansk University of Physical Education and Sport
Carnitine Supplementation and Skeletal Muscle Function in Aging
The primary aim of the current research project is to explore whether leucine stimulates carnitine transport, and thus affecting muscle carnitine content.
A secondary aim of this project is to investigate the effect of carnitine with leucine supplementation on muscle strength and body composition.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 29 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- must be able to swallow tablets
Exclusion Criteria:
- cardiovascular disease
- liver disease
- kidney disease
- neuromuscular disease
- gastrointestinal disorders (including stomach ulcers and erosions)
- diabetes
- other severe chronic diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: carnitine + leucine
1000 mg L-carnitine with 3000 mg L-leucine per day for 24 weeks
|
Other Names:
|
Placebo Comparator: leucine
4000 mg L-leucine per day for 24 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Muscle Carnitine Concentration using UPLC-MS/MS
Time Frame: 24 weeks
|
vastus lateralis muscle biopsy taken before and after the supplementation procedure (~20 cm proximal to the knee joint using a thin biopsy needle); carnitine concentration determined using ultra performance liquid chromatography - tandem mass spectrometer (UPLC-MS/MS) method
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Muscle Strength using Biodex System 4 Pro dynamometer
Time Frame: 24 weeks
|
Peak torque measured by performing maximum voluntary contractions during isometric knee extension and flexion.
The test performed in concentric-concentric mode consisting maximum 4-s knee extensor isometric contraction and maximum 4-s knee flexor isometric contraction, separated by 20-s recovery, repeated three times.
Muscle isokinetic strength assessed in 5 repetitions of flexion and extension at a speed of 60°/s.
Muscle endurance assessed in 10 repetitions at 300°/s determine the ability of the muscle to maintain the work.
Strength testing performed on the Biodex System 4 Pro dynamometer.
|
24 weeks
|
Body Composition: Body Fat Mass, Fat Free Mass, and Skeletal Muscle Mass using a bioelectrical impedance analyzer (InBody720).
Time Frame: 24 weeks
|
The InBody720 measures impedance of five segments of the body (each arm, each leg, trunk) at frequencies of 1, 5, 50, 250, 500, and 1000 kHz through the 8-polar tactile-electrode.
Based on the impedance, body fat mass, fat free mass, and skeletal muscle mass are calculated.
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2016
Primary Completion (Actual)
May 15, 2017
Study Completion (Actual)
January 31, 2018
Study Registration Dates
First Submitted
August 5, 2021
First Submitted That Met QC Criteria
August 11, 2021
First Posted (Actual)
August 17, 2021
Study Record Updates
Last Update Posted (Actual)
August 17, 2021
Last Update Submitted That Met QC Criteria
August 11, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- NCN_ROL
- 2014/15/B/NZ7/00893 (Other Grant/Funding Number: National Science Centre)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Muscle Loss
-
United States Army Research Institute of Environmental...US Army Natick Soldier Research, Development & Engineering CenterCompletedMuscle Loss | Muscle Anabolism | Muscle PerformanceUnited States
-
United States Army Research Institute of Environmental...Tufts UniversityCompletedMuscle Loss | Muscle AnabolismUnited States
-
Zhejiang UniversityHuashan Hospital; West China Hospital; The Affiliated Hospital of Qingdao University and other collaboratorsNot yet recruitingLiver Transplantation | Muscle Loss | Muscle Quality
-
Göteborg UniversityCompleted
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Orient Europharma Co., Ltd.Completed
-
Lancaster UniversityCompleted
-
Investigación en Hemofilia y FisioterapiaCompleted
-
The University of Texas Medical Branch, GalvestonNational Space Biomedical Research InstituteCompleted
-
Maastricht University Medical CenterCompleted
Clinical Trials on L-carnitine
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Ain Shams UniversityCompleted
-
Vanderbilt University Medical CenterCompletedLung Diseases | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Primary Pulmonary Hypertension | Carnitine Nutritional DeficiencyUnited States
-
Toujinkai HospitalCompletedDisorder of Fatty Acid Metabolism
-
Bahria UniversityUniversity of Karachi; Jinnah Postgraduate Medical Centre; Pakistan Navy Station...RecruitingHemodialysis ComplicationPakistan
-
HealthPartners InstituteTerminatedBreast Cancer | Neurotoxicity | Chemotherapeutic Agent ToxicityUnited States
-
National Taiwan University HospitalRecruitingGut Dysbiosis for TMAO Production From L-carnitine ConsumptionTaiwan
-
Ain Shams UniversityActive, not recruitingl Carnitine With Ketogenic DietEgypt
-
Heba Allah Ali Abd El-Halim MabroukTanta UniversityCompleted
-
Kochi UniversityUnknown